Like Costco, Walmart to sell Medicare Advantage plans

Walmart will offer co-branded Medicare Advantage plans with nonprofit insurer SCAN Health in two unnamed states, with enrollment beginning Oct. 15. The initiative follows a similar SCAN partnership with Costco and aims to lower healthcare costs by encouraging healthier member behavior. The limited initial rollout is a modest expansion of Walmart's healthcare-related offerings.

Analysis

The economic value is unlikely to sit with the retail brands in the first enrollment cycle; it depends on whether SCAN can turn store traffic, pharmacy engagement, and member data into lower medical-loss ratios and higher Stars ratings. WMT has a potentially stronger monetization path than COST because its pharmacy footprint, grocery frequency, and value-oriented customer base create more recurring touchpoints to influence medication adherence and preventive care. Even so, any near-term earnings contribution should be immaterial relative to WMT’s retail base, making this primarily an option on healthcare-services adjacency rather than a retail catalyst.

The more important competitive effect is pressure on regional Medicare Advantage carriers with weak distribution economics. Retail-led acquisition can reduce broker commissions and improve retention, while a credible low-cost plan may force local carriers to spend more on supplemental benefits or marketing; HUM is the most exposed public proxy where county-level competition intensifies, though the two-state scope is currently too narrow for a broad short. CVS/Aetna is less directly threatened because it has an integrated care-delivery and PBM stack, but retail enrollment partnerships reinforce the strategic value of its pharmacy network.

The 1-3 month catalyst is plan-benefit disclosure and early enrollment evidence during the annual election period; the key data are premium, dental/vision benefits, network breadth, county footprint, and whether WMT pharmacies receive preferred cost-sharing status. The 6-18 month risk is adverse selection: retail branding may attract cost-sensitive beneficiaries without necessarily improving risk-adjusted medical costs, while CMS rate and risk-adjustment changes can overwhelm any distribution advantage. A meaningful thesis requires evidence that SCAN gains membership at acceptable acquisition cost and sustains Stars performance, not simply plan availability.

Key Decisions for Investors

• No standalone directional trade in WMT or COST on launch news; maintain WMT as the preferred retail exposure only if management identifies healthcare-services revenue or pharmacy/member-engagement KPIs in the next two earnings calls. Falsifier: no expansion beyond pilot states or no evidence of pharmacy linkage by the 2027 plan year.
• Create an Oct. 15 watch item for CMS plan files: compare co-branded plan premiums, MOOP, supplemental benefits, provider networks, and preferred-pharmacy status against local HUM and CVS/Aetna offerings. Escalate only if benefits are materially richer without an obvious premium offset, signaling subsidized share capture.
• For a 6-12 month relative-value expression, consider long WMT versus short HUM only after enrollment data show county-level share gains in overlapping markets. Target a 5-8% relative move; stop if SCAN enrollment is de minimis or HUM demonstrates offsetting benefit redesign and stable medical-cost guidance.
• Monitor SCAN’s Stars ratings and any CMS enforcement or risk-adjustment updates. A downgrade, elevated utilization, or unfavorable CMS reimbursement decision would invalidate the assumed cost-management advantage and turn the retailer partnership into a marketing expense rather than a margin opportunity.